Dr Errol De Souza PhD
Executive Chairman

Dr De Souza is a leader in the development of therapeutics for treatment of central nervous system (CNS) disorders. He is currently the President and CEO of Neuropore Therapies Inc. He was formerly President and CEO of a leading US company Biodel Inc (Nasdaq: BIOD) and is the former President and CEO of US biotech companies Archemix Corporation and Synaptic Pharmaceutical Corporation. Dr De Souza formerly held senior management positions at Aventis and its predecessor Hoechst Marion Roussel Pharmaceuticals, Inc. Most recently, he was Senior Vice President and Site Head of US Drug Innovation and Approval (R&D), at Aventis, where he was responsible for the discovery and development of drug candidates through Phase IIa clinical trials for CNS and inflammatory disorders. Prior to Aventis, he was a co-founder and Chief Scientific Officer of Neurocrine Biosciences (Nasdaq: NBIX). Dr DeSouza has served on multiple editorial boards, National Institutes of Health (NIH) Committees and is currently a Director of several public and private companies.

Mr Peter Turner BSc, MBA, GAICD
Non-Executive Director

Peter Turner is a former senior executive with global experience in CSL Limited, a large multinational organization in the biopharmaceutical industry. He has been an executive director and COO of CSL and was the founding President of CSL Behring working in Europe and the United States from 2000 - 2011. Mr Turner provided strategic, technical and commercial leadership and was responsible for the integration of large company acquisitions in Europe, the United States and Japan. He has been responsible for significant company re-structuring and turnaround and has overseen 13 new product launches in the United States and Europe and more in other jurisdictions. During his tenure overseas, sales grew from US$140 million to US$3.4 billion per annum.

Peter is a non-executive director of Virtus Health and the Chair of NPS MedicineWise.  He is former Chair of Ashley Services Group. 

Mr David Wilson
Non-Executive Director

Mr Wilson is Chairman and founding partner of WG Partners and has over 30 years' experience in the City of London. Previously he was CEO of Piper Jaffray Ltd, where he also served as Global Chairman of Healthcare and on the Group Leadership Team. Mr Wilson has held senior positions at ING Barings as Joint Head of UK Investment Banking Group, Deutsche Bank as Head of Small Companies Corporate Finance and UBS as Head of Small Companies Corporate Broking. He was previously Senior Independent Director of Optos plc prior to its successful sale of Nikon Corporation for c.$400m as well as a non-executive director of BerGenBio AS. He is currently on the Board of Governors of Harris Academy Bromley. 

Mr Alan Fisher BCom, FCA, MAICD
Non-Executive Director

Mr Fisher has extensive and proven experience in restoring and enhancing shareholder value.  He spent 24 years at world-leading accounting firm Coopers & Lybrand as Lead Advisory Partner where he headed and grew the Melbourne Corporate Finance Division.  Following this tenure Mr Fisher developed his own business as a corporate advisor and for the past 19 years has specialised in M&A, business restructurings, strategic advice and capital raisings for small cap companies.  He is currently Non-Executive Chairman of Centrepoint Alliance Limited, and Chair of IDT Australia Limited.  He is also the Managing Director of DMC Corporate.  He holds a Bachelor of Commerce from Melbourne University, is a Fellow of the Institute of Chartered Accountants Australia and a Member of the Australian Institute of Company Directors. 

Mr Mitchell Kaye
Non-Executive Director

Mitchell Kaye, J.D., joined BVF Partners L.P. in 2013. Mr. Kaye was the founding member of Xmark Opportunity Partners, LLC, an investment fund exclusively focused on investments in publicly traded life sciences companies and was also a founding member of Brown Simpson Asset Management, LLC, an investment fund that was at the foreground of private placement investing in the public markets.  He ran the two funds from 2001-2008 and 1996-2001, respectively.  Mr. Kaye was the Founder of MedClaims Liaison, LLC, a consumer advocacy business, and served as its Chief Exectutive Officer from its inception in 2010 until he joined BVF.  From 2008-2010, Mr. Kaye was a Managing Director with Navigant Capital Advisors, a financial and strategic advisory services firm, and head of Navigant's Financial Institutions Restructuring Solutions Team.  Mr. Kaye currently serves on the board of Bionomics.  He has served on the boards of several private and public companies, as well as the board of the New York Alzheimer's Association.  Mr. Kaye received his B.A. from Wesleyan University, and his J.D. from Northwestern University School of Law.